Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 9/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | TRHR | P34981 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8426408 | 1.00 | HDAC3 (0.36) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL17995 | 0.94 | HDAC3 (0.36) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL2132866 | 0.87 | — | — | |
| SCHEMBL3134625 | 0.87 | — | — | |
| SCHEMBL8920712 | 0.87 | — | — | |
| SCHEMBL15347243 | 0.83 | HDAC3 (0.38) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL630497 | 0.81 | CAD (0.43) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL3625069 | 0.81 | CAD (0.43) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL2344195 | 0.81 | CAD (0.43) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL14374129 | 0.79 | GLI1 (0.44) | HDAC3HDAC11HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445874-B1 | PROCESS OF PREPARATION OF 2-ACETYL-1-PYRROLINE AND A STABLE PRECURSOR THEREOF, ISOTOPICALLY LABELLED OR NOT | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-11-29 | — | — | EP | disclosed |
| EP-2445874-B1 | PROCESS OF PREPARATION OF 2-ACETYL-1-PYRROLINE AND A STABLE PRECURSOR THEREOF, ISOTOPICALLY LABELLED OR NOT | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-11-29 | — | — | EP | disclosed |
| US-8597706-B2 | Method for synthesizing 2-acetyl-1-pyrroline, stable ketal precursors thereof, and isotopically marked analogs | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2013-12-03 | — | — | US | disclosed |
| EP-2445874-A1 | METHOD FOR SYNTHESISING 2-ACETYL-1-PYRROLINE AND THE STABLE PRECURSOR THEREOF, OPTIONALLY ISOTOPICALLY MARKED | Centre National De La Recherche Scientifique CNRS (FR) | 2012-05-02 | — | — | EP | disclosed |
| US-20120100274-A1 | METHOD FOR SYNTHESISING 2-ACETYL-1-PYRROLINE AND THE STABLE PRECURSOR THEREOF, OPTIONALLY ISOTOPICALLY MARKED | UNIVERSITE DE MONTPELLIER (FR) | 2012-04-26 | — | — | US | disclosed |
| US-20120100274-A1 | METHOD FOR SYNTHESISING 2-ACETYL-1-PYRROLINE AND THE STABLE PRECURSOR THEREOF, OPTIONALLY ISOTOPICALLY MARKED | UNIVERSITE DE MONTPELLIER (FR) | 2012-04-26 | — | — | US | disclosed |
| US-20120100274-A1 | METHOD FOR SYNTHESISING 2-ACETYL-1-PYRROLINE AND THE STABLE PRECURSOR THEREOF, OPTIONALLY ISOTOPICALLY MARKED | UNIVERSITE DE MONTPELLIER (FR) | 2012-04-26 | — | — | US | disclosed |
| WO-2010149744-A1 | METHOD FOR SYNTHESISING 2-ACETYL-1-PYRROLINE AND THE STABLE PRECURSOR THEREOF, OPTIONALLY ISOTOPICALLY MARKED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010149744-A1 | METHOD FOR SYNTHESISING 2-ACETYL-1-PYRROLINE AND THE STABLE PRECURSOR THEREOF, OPTIONALLY ISOTOPICALLY MARKED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-12-29 | — | — | WO | disclosed |
| US-7829561-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| US-20090023739-A1 | interleukin-1B converting enzyme inhibitors such as 3-(6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid, that mediate cell apoptosis and inflammation, used for cell or organ preservation and the treatment of osteoarthritis and rheumatoid arthritis | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-01-22 | — | — | US | disclosed |
| US-7407964-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-05 | — | — | US | disclosed |
| EP-0522533-A1 | Process for polymerizing epsilon-caprolactam | UNITIKA LTD. (JP) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023739-A1 | interleukin-1B converting enzyme inhibitors such as 3-(6,11-Dioxo-1,2,3,4-tetrahydro-pyridazino[1,2-b]phthalazin-1-carboxamido)-5-fluoro-4-oxo-pentanoic acid, that mediate cell apoptosis and inflammation, used for cell or organ preservation and the treatment of osteoarthritis and rheumatoid arthritis | IL1B, IL1RN, CASP1 | HDAC3 595/4885HDAC11 1050/4885HDAC6 1636/4885 |
| US-20120100274-A1 | METHOD FOR SYNTHESISING 2-ACETYL-1-PYRROLINE AND THE STABLE PRECURSOR THEREOF, OPTIONALLY ISOTOPICALLY MARKED | SAT1, PDHA1, PTMS | HDAC3 464/4885HDAC11 285/4885HDAC6 721/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | HDAC3 452/4885HDAC11 365/4885HDAC6 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.